Clinical trials: Dabrafenib
Melanoma
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
This is a prospective, open label, single-arm, multicenter, non-interventional study of dabrafenib in combination with trametinib as adjuvant treatment for Chinese patients with stage III BRAF V600 mutation positive melanoma…
- Trial name
- NCT04666272
- Testing
- dabrafenib, trametinib
- Where
- 8 sites in China
- Volunteers
- 78 people
- Sponsor
- Novartis Pharmaceuticals